A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma.
A new approach for removing the anti-factor VIII antibodies in hemophilic patients by immunoadsorption is proposed. The method is based on the fact that the anti-factor VIII antibodies were predominantly of the IgG4 subclass; anti-human IgG4 antibodies were covalently linked to agarose and large amounts of anti-factor VIII antibodies can be eliminated. A study of 21 blood samples from hemophilic patients with anti-factor VIII antibodies allows us to confirm the large predominance of IgG4 in the anti-factor VIII population. In some samples, the presence of IgG3 related anti-VIII:C was checked by adsorption on an anti-IgG3 column. In a majority of cases, after IgG4 (or IgG4 + IgG3) immunoadsorption, the substitution therapy becomes possible or easier.
D000918:Antibody Specificity; D001323:Autoantibodies / Q000276:immunology / Q000302:isolation & purification*; D005169:Factor VIII / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000378:metabolism; D007163:Immunosorbent Techniques; D011485:Protein Binding; D012685:Sepharose / Q000378:metabolism
D001323:Autoantibodies; D007074:Immunoglobulin G; D005169:Factor VIII; D012685:Sepharose